aortic diameter ratio > 1.6 on an M-mode or 2-dimensional short axis view), and had radiographic evidence of cardiomegaly. Dogs with systemic hypertension, radiographic evidence of pulmonary edema, or concurrent disease processes that, in the opinion of the investigator, would result in death in < 1 year were excluded. Owners of dogs included in the study provided informed consent.
Dogs enrolled in the enalapril efficacy trial were eligible for inclusion in the present study if serum creatinine and urea nitrogen concentrations had been measured before and at least once after initiation of treatment with enalapril. Serum creatinine and urea nitrogen concentrations were measured, using validated procedures, at the participating institutions or by private commercial laboratories.
Treatment and monitoring-For all dogs, a complete physical examination, echocardiographic and thoracic radiographic examinations, and laboratory evaluations (CBC, urinalysis, and serum biochemical profile) were performed at the time of enrollment in the study. Dogs were then randomly assigned to be treated with enalapril (0.5 mg/kg [0.23 mg/lb], PO, q 24 h) or a placebo. Owner compliance was determined by a combination of owner interrogation, examination of daily pill administration logs, and pill counts; dogs were removed from the study if owner compliance was inadequate. Serum urea nitrogen and creatinine concentration were measured at the time of enrollment in the study; approximately 0.5, 3, 6, 9, 12, 15, and 18 months later; and approximately every 4 months thereafter, as needed. In addition, if signs compatible with heart failure (cough or dyspnea) were detected during a routine follow-up examination or were reported by the owner, the dog was reevaluated and thoracic radiographs obtained. Once congestive heart failure, defined as radiographic evidence of pulmonary edema, developed, the group assignment code was broken, and the dog was treated as deemed necessary by the attending clinician. Group assignment (enalapril or placebo) of each dog enrolled in the study was known by only 1 person (JRC), the lead technician in the study, who played no role in clinical decision-making.
Statistical analyses-The integrity of the primary study was the highest priority; therefore, interim analyses were performed with great care to avoid disclosure of the status of individual dogs. Interim analyses of renal safety at approximately 12 and 24 months and final analysis at 38 months were performed by identifying dogs only as being in group 1 or 2 (without breaking the code), after scrambling the order of patients within each group and removing identifying notations as to patient and clinic. For the final renal safety analysis, the code was broken 42 months after study initiation, when patient entry (n = 139) was complete. Before the code was broken, all identifying patient and clinic notations were again deleted, the order of patients within each group was scrambled, and statistical analyses were completed and conclusions drawn.
Age, sex distribution, and proportion of dogs that dropped out of the study were compared between groups (enalapril vs placebo) with t tests or χ 2 tests. Serum creatinine and urea nitrogen concentrations at the time of enrollment (baseline) and at each recheck time (0.5 and approx 3, 6, 9, 12, 15, 18, 22, and 26 months) after initiation of treatment were compared between groups with t tests. In addition, repeated-measures ANOVA was performed to identify potential sources of variation within and between groups with respect to treatment, time, and the interaction of treatment and time. Serum creatinine and urea concentrations were plotted for each dog, and linear regression analysis was used to determine the rate of change in serum concentrations (ie, the slopes of the linear regression lines) from the time of enrollment to the final measurement. Slopes of the linear regression lines for dogs in each group were then compared with ANOVA. Proportions of dogs in each group in which serum creatinine or urea nitrogen concentration increased ≥ 35%, compared with concentration at the time of enrollment, and proportions of dogs in each group that developed azotemia (serum creatinine concentration > 1.8 mg/dl) were compared between groups with χ 2 tests. For all analyses, values of P < 0.05 were considered significant.
Results
In total, 139 dogs were enrolled in the trial of enalapril efficacy (70 in the enalapril group and 69 in the placebo group). At the time of the present study, 55 of these dogs had completed the trial (ie, they had developed congestive heart failure), 36 had dropped out, and 48 were still enrolled in the trial. Reasons for dogs dropping out of the trial included death (2 in the enalapril group and 4 in the placebo group), death or euthanasia secondary to noncardiac disease (4 in the enalapril group and 7 in the placebo group), owner death or relocation (2 in the enalapril group), other disease (3 in the enalapril group and 3 in the placebo group), and owner noncompliance (5 in the enalapril group and 6 in the placebo group). In 1 dog, baseline serum creatinine and urea nitrogen concentrations were not available, because a blood sample was lost. In an additional 6 dogs, serum creatinine and urea nitrogen concentrations were not measured after initiation of enalapril treatment, because the dog completed or dropped out of the study before a second sample could be obtained. Therefore, 132 dogs were included in the present study (64 in the enalapril group and 68 in the placebo group).
For the present study, sex distribution of dogs in the enalapril group (50% males) was not significantly different from sex distribution of dogs in the placebo group (45% males); mean ± SD age of dogs in the enalapril group (10.0 ± 2.1 years) was not significantly different from mean age of dogs in the placebo group (10.5 ± 2.3 years); and mean body weight of dogs in the enalapril group (7.8 ± 3.5 kg [17.2 ± 7.7 lb]) was not significantly different from mean body weight of dogs in the placebo group (8.8 ± 4.4 kg [19.4 ± 9.7 lb]). In addition, proportion of dogs in the enalapril group that dropped out of the study (16/70) was not significantly different from the portion of dogs in the placebo group that dropped out of the study (20/69).
Serum samples were available from all 132 dogs at the time of enrollment in the study and 2 weeks after initiation of enalapril treatment. Because of dogs completing and dropping out of the study, serum samples were available from only 119 dogs (58 in the enalapril group and 61 in the placebo group) at 3 months, 102 dogs (50 in the enalapril group and 51 in the placebo group) at 6 months, 85 dogs (47 in the enalapril group and 38 in the placebo group) at 9 months, 69 dogs (36 in the enalapril group and 33 in the placebo group) at 12 months, 47 dogs (25 in the enalapril group and 22 in the placebo group) at 14 months, 35 dogs (20 in the enalapril group and 15 in the placebo group) at 18 months, 22 dogs (11 in the enalapril group and 11 in the placebo group) at 22 months, and 14 dogs (7 in the enalapril group and 7 in the placebo group) at 26 months. One dog in the enalapril group was azotemic (serum creatinine, 2.1 mg/dl) at the time of enrollment.
Mean serum creatinine concentrations were not significantly different between groups at any time during the study (Fig 1) . Similarly, mean serum urea nitrogen concentrations were not significantly different between groups at any time (Fig 2) . Neither group had a significant change in serum creatinine concentration, compared with baseline concentration, at any time during the study, and ANOVA did not reveal any change in serum creatinine concentration over time in either group. There was a statistically (P = 0.043), but not clinically, significant increase in urea nitrogen concentration over time in both groups, as determined by ANOVA. The magnitude of this increase was small, equivalent between groups, and statistically unrelated to treatment.
Five dogs developed azotemia (serum creatinine concentration > 1.8 mg/dl) at 1 time point during the study. One dog in the enalapril group had a serum creatinine concentration of 2.6 mg/dl at 9 months, and 1 had a concentration of 2.1 mg/dl at 22 months. Two dogs in the placebo group had serum creatinine concentrations of 2.2 mg/dl at 3 and 15 months, and a third, with pyelonephritis, had a serum creatinine concentration of 4.9 mg/dl at 18 months.
There was no significant difference between groups in regard to proportion of dogs that had a ≥ 35% increase, compared with baseline concentration, in serum creatinine (12 dogs in the enalapril group and 17 in the placebo group) or serum urea nitrogen (40 dogs in the enalapril group and 37 in the placebo group) concentration. Four dogs in the enalapril group and 5 dogs in the placebo group had a ≥ 35% increase in serum creatinine concentration, compared with baseline concentration, at 0.5 months; 4 dogs in the enalapril group and 9 dogs in the placebo group had a ≥ 35% increase in serum creatinine concentration at 3 months; and 2 dogs in the enalapril group and 3 dogs in the placebo group had a ≥ 35% increase in serum creatinine concentration at both 0.5 and 3 months.
The dog that was azotemic at the time of enrollment remained in the study and received enalapril for 18 months; at the time of completion of the study, serum creatinine concentration was 1.8 mg/dl. Six additional dogs (3 in each group) had serum urea nitrogen concentration > 28 mg/dl at the time of enrollment. None of the 3 dogs that received enalapril ever had a serum urea concentration > 45 mg/dl. No dogs dropped out of the study because of treatmentinduced azotemia. One dog in the placebo group dropped out at 18 months after becoming azotemic (serum creatinine, 4.9 mg/dl), but this dog had pyelonephritis. Results were not different when this dog was excluded from analyses.
Discussion
Results of the present study suggested that longterm (up to 26 months) administration of enalapril (0.5 mg/kg, PO, q 24 h) to dogs with severe, compensated mitral regurgitation did not have any adverse effects on renal function. Not only were there no differences between groups (enalapril vs placebo) in regard to serum creatinine and urea nitrogen concentrations at any time, there also were no differences in regard to change from baseline concentration or the proportion of dogs that had a ≥ 35% increase in serum creatinine or urea nitrogen concentration. In addition, although azotemia (serum creatinine concentration > 1.8 mg/dl) was occasionally noticed in both groups, it was mild, and the frequency of azotemia was not significantly different between groups. No dogs dropped out of the study because of drug-induced renal failure, although 1 dog in the placebo group dropped out of the study because of pyelonephritis and renal failure.
In the present study, serum creatinine and urea nitrogen concentrations were used as indicators of renal function, as both can be easily measured in clinical practice and serum creatinine concentration has been shown to be a reliable and specific indicator of renal function.
14 Serum creatinine and urea nitrogen concentrations were compared between groups in a blinded fashion, in that all analyses were performed before the group assignment code was broken. Not only were serum creatinine and urea nitrogen concentrations compared between groups in the present study, but proportions of dogs that had a ≥ 35% increase in serum creatinine or urea nitrogen concentration were also compared between groups. The cutoff of a ≥ 35% increase in concentration was chosen because previous authors 15 suggested that a < 30% increase in serum creatinine concentration was indicative of efficacy and predictive of improved renal function and because a 30 to 40% increase was considered to be indicative of a decrease in renal function in previous studies of human patients. 16, 17 Concerns about the renal safety of ACE inhibitors have arisen because angiotensin II is known to have a preferential vasoconstrictive effect on the efferent renal arteriole and is, therefore, important in maintaining glomerular filtration pressure. 5 Thus, an ACE inhibitor-induced reduction in angiotensin II concentration (and, possibly, an increase in bradykinin concentration) may decrease glomerular filtration rate and induce azotemia, particularly in human patients with diminished afferent arteriolar or perfusion pressure (eg, patients in heart failure, with renal artery stenosis, or in a hypovolemic state). 5 Although this renal dysfunction is typically reversible, renal failure may develop as a result of drug-induced hypotension. 5, 11, 18 An early experimental study 10 involving dogs suggested that renal impairment could result from administration of ACE inhibitors at very high dosage (eg, 120 times the recommended starting dosage). Clinical experience has also suggested that renal impairment might result from hypotension in susceptible individuals (eg, those with heart failure, renal artery stenosis, or volume contraction) given ACE inhibitors at clinically appropriate dosages. 5, 11, 18 On the other hand, although there is a risk of adverse effects in certain patients, particularly when used in conjunction with diuretics and a sodium-restricted diet, 10 the overall negative impact of ACE inhibitors in patients with heart failure has been minimal. In addition, in previous clinical trials 9,19 of dogs with heart failure treated with benazepril or a placebo, the proportions of dogs that became azotemic or developed renal failure was not significantly different between groups. In fact, there are now data to suggest that renal function improves with ACE inhibitor treatment in humans, dogs, and cats with a variety of renal diseases, particularly those involving the glomerulus.
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Although the overall safety record of enalapril in veterinary medicine has been exemplary, studies in dogs have been relatively short-term (20 days to approx 4 months). [6] [7] [8] In addition, the longest ACE inhibitor study 9 (8 months) used a relatively low dosage of benazepril (starting dosage, 0.25 mg/kg, PO, q 24 h). The present study was designed to determine renal effects when enalapril was administered for a longer term at a clinically appropriate dosage to dogs with severe mitral regurgitation but without congestive heart failure (New York Heart Association class I or II). In 69 of the 132 dogs in this study, renal function was evaluated for at least 1 year after initiation of enalapril treatment, and in 14, renal function was evaluated for > 2 years.
The present study was part of an ongoing trial investigating whether enalapril could delay the onset of congestive heart failure in dogs with severe mitral regurgitation if treatment was instituted after evidence of left atrial enlargement was apparent but before pulmonary edema had developed. Previous studies 2, 3, 21 have suggested that ACE inhibitor treatment may be of benefit in people at risk of heart failure. In addition, some evidence suggests that ACE inhibitors may help delay the onset of heart failure in dogs as well. Pederson Although the present study was a part of a randomized controlled trial, there were, nevertheless, certain limitations. First, the number of patients was small, with < 70 dogs in each group. Second, although the duration of treatment was longer than in previous studies and germane to the life expectancy of aged dogs with heart disease, median follow-up time was only 12 months, and only 14 dogs were followed up for > 2 years. Third, these data apply to aged dogs with cardiomegaly secondary to mitral regurgitation and may not apply to dogs with other heart diseases or with certain pre-existing renal diseases. Fourth, the possibility that enalapril-induced improvements in hemodynamic status, with resultant increases in glomerular filtration rate, might have masked direct deleterious effects on renal function cannot be ruled out on the basis of results of the present study. Additionally, although there was no evidence of drug interactions in this study, concurrent drug treatments and their possible interactions with enalapril were not specifically monitored. Lastly, and most importantly, although serum creatinine concentration is the most specific of the common indicators of renal function, it and serum urea nitrogen concentration are relatively insensitive. Hence, mild alterations in renal function may not have been detected. 
